List of Excipients in Branded Drug OLANZAPINE

« Back to Dashboard

Generic Drugs Containing OLANZAPINE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	olanzapine	0093-5245	ASPARTAME
Teva Pharmaceuticals USA Inc	olanzapine	0093-5245	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	olanzapine	0093-5245	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	olanzapine	0093-5245	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	olanzapine	0093-5245	MANNITOL
Teva Pharmaceuticals USA Inc	olanzapine	0093-5245	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in OLANZAPINE?

# Of NDCs	Excipient
1	ACESULFAME POTASSIUM
2	ALUMINUM OXIDE
1	AMMONIA
11	ANHYDROUS LACTOSE
20	ASPARTAME
3	BENZYL ALCOHOL

Olanzapine Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: September 26, 2026

Olanzapine is a mature generic antipsychotic with limited molecule-level exclusivity but continuing formulation opportunities. The strongest commercial positions are in orally disintegrating tablets, taste-masked multiparticulates, long-acting injectable systems, pediatric-friendly liquids, and manufacturing platforms that improve content uniformity and dissolution. Standard immediate-release tablets face intense price competition, while differentiated delivery systems can support 505(b)(2) applications, hospital contracts, specialty distribution, or regional licensing.

What is the FDA and commercial status of olanzapine?

Olanzapine is an atypical antipsychotic approved for schizophrenia and bipolar I disorder. It is marketed orally as immediate-release tablets and orally disintegrating tablets, and as a long-acting intramuscular formulation of olanzapine pamoate monohydrate. The reference product is Zyprexa, marketed by Eli Lilly, while Zyprexa Zydis is the orally disintegrating presentation and Zyprexa Relprevv is the long-acting injectable product.

Product	Active ingredient	Dosage form	Original sponsor	Current commercial position
Zyprexa	Olanzapine	Immediate-release tablet	Eli Lilly	Originator product; generic competition
Zyprexa Zydis	Olanzapine	Orally disintegrating tablet	Eli Lilly	Generic ODT competition; formulation differentiation remains possible
Zyprexa Relprevv	Olanzapine pamoate monohydrate	Long-acting intramuscular suspension	Eli Lilly	Specialized product with substantial administration and manufacturing barriers
Generic olanzapine	Olanzapine	Tablets and ODTs	Multiple manufacturers	Commodity-to-mid-margin generic market

The FDA approved Zyprexa in 1996, Zyprexa Zydis in 2000, and Zyprexa Relprevv in 2009. The original olanzapine compound patent, U.S. Patent No. 5,229,382, expired in 2011 after applicable patent-term adjustments and pediatric exclusivity were considered. Olanzapine therefore has no meaningful remaining compound exclusivity in the United States (FDA, 2024a; USPTO, 2024).

When does olanzapine lose exclusivity?

Olanzapine lost core small-molecule exclusivity more than a decade ago. Commercial protection now depends on formulation, device, manufacturing, regulatory, and execution barriers rather than the active ingredient.

Protection category	Historical position	Current relevance
Compound patent	U.S. Patent No. 5,229,382; expired in 2011	No remaining broad compound barrier
New chemical entity exclusivity	Associated with 1996 approval	Expired
Immediate-release tablet patents	Historical formulation and process coverage	Generally expired or commercially weak
ODT patents	Covered rapid disintegration, excipient systems, and manufacturing	Many historical claims expired; new improvement patents may be available
Long-acting injectable patents	Product, salt, particle, suspension, and manufacturing claims	Potentially more relevant, depending on jurisdiction and claim scope
Method-of-use patents	Schizophrenia, bipolar disorder, and related uses	Limited value where labeled uses are old and generic labeling is established
Regulatory exclusivity	No current U.S. exclusivity for standard olanzapine tablets	Generic approval pathway remains open

The main commercial conclusion is that a new olanzapine product must compete through delivery, adherence, tolerability, administration convenience, supply reliability, or market access. A conventional tablet with a different excipient grade is unlikely to support durable pricing unless it solves a documented manufacturing or bioequivalence problem.

What excipients are used in olanzapine tablets?

Olanzapine is a low-dose, poorly water-soluble compound. Excipient selection must address powder flow, low-dose content uniformity, dissolution, tablet robustness, moisture sensitivity, and patient acceptability.

Common immediate-release tablet excipient classes include:

• Diluent and compression aids such as lactose, microcrystalline cellulose, mannitol, or dibasic calcium phosphate.
• Disintegrants such as crospovidone, croscarmellose sodium, or sodium starch glycolate.
• Binders such as povidone, copovidone, hydroxypropyl cellulose, or pregelatinized starch.
• Lubricants such as magnesium stearate, sodium stearyl fumarate, or stearic acid.
• Glidants such as colloidal silicon dioxide.
• Film-coating systems based on hypromellose, polyvinyl alcohol, polyethylene glycol, and titanium dioxide or iron oxides.

The commercial challenge is balancing dissolution with mechanical strength. Excessive lubricant can reduce wetting and slow dissolution. Excessive binder can produce hard tablets with delayed disintegration. High levels of hydrophilic polymer may improve compactability but can also increase tablet swelling, sticking, or scale-up variability.

For a low-dose olanzapine tablet, content uniformity is often more important than absolute drug loading. Segregation between API and excipient particles can cause assay variation, particularly when direct compression is used. Granulation, ordered mixing, co-processing, or carrier-based deposition can reduce this risk.

What excipient strategies are strongest for immediate-release olanzapine?

A conventional generic strategy should prioritize robust bioequivalence and low manufacturing cost. The most practical options are:

Direct-compression formulation

Direct compression offers a short process and low capital burden. It requires an excipient blend with controlled particle-size distribution, adequate flow, and consistent lubricant sensitivity. Co-processed microcrystalline cellulose and mannitol systems can improve flow and mouthfeel, but the formulation must be screened for segregation and dissolution drift.

Wet granulation

Wet granulation can improve content uniformity and reduce segregation. It may be useful when the API has poor flow or a wide particle-size distribution. The process introduces additional risk from residual moisture, polymorphic changes, granule overgrowth, and longer manufacturing time.

Dry granulation

Roller compaction may provide a middle path for manufacturers seeking improved flow without water exposure. It can reduce fines and improve tablet weight control. Excessive compaction force can reduce porosity and slow olanzapine dissolution.

Amorphous or particle-engineered API

Amorphous dispersions, micronization, nanocrystals, and spray-dried systems can improve dissolution. These approaches create a stronger technical story but also introduce stability, scale-up, and control-strategy requirements. A formulation relying on an amorphous olanzapine phase must control recrystallization during storage.

For a standard generic, particle engineering should be pursued only when conventional formulation cannot meet dissolution or bioequivalence targets. For a differentiated product, it can support composition, process, and product-by-process claims.

What excipients protect olanzapine orally disintegrating tablets?

Olanzapine ODTs are the clearest excipient-driven commercial segment. The product must disintegrate rapidly in the mouth while maintaining adequate hardness for packaging and transport. Taste masking is critical because olanzapine can produce an unpleasant mouthfeel.

A practical ODT platform may include:

Functional objective	Excipient strategy
Rapid disintegration	Crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose
Mouthfeel	Mannitol, xylitol, erythritol, or other low-grit polyols
Taste masking	Polymer coating, ion-exchange resin, cyclodextrin complexation, lipid coating, or multiparticulate encapsulation
Tablet strength	Microcrystalline cellulose, copovidone, or optimized compression force
Low moisture uptake	Low-hygroscopic fillers, protective packaging, desiccants
Flavor correction	Flavors and sweeteners compatible with the API and stability profile
Manufacturing robustness	Granulation or co-processed excipient systems

The principal patent opportunity is not the use of mannitol or crospovidone alone. Those excipients are widely known. Stronger claim strategies combine:

1. A defined olanzapine particle-size distribution.
2. A specific taste-masking coating or complex.
3. A narrow disintegration-time range.
4. A dissolution profile that supports bioequivalence or improved onset.
5. A moisture-resistant package and tablet composition.
6. A manufacturing sequence that produces consistent low-dose distribution.

Historical Zydis technology created a high benchmark for rapid disintegration and patient acceptability. A competing product must show either a cost advantage, improved physical robustness, stronger taste masking, simpler packaging, or a regulatory pathway that avoids unnecessary formulation complexity.

What formulations are protected by olanzapine patent estates?

The historical olanzapine patent estate includes compound, formulation, dosage-form, and manufacturing concepts. The broadest compound protection is expired. Remaining or newly filed protection, where available, is more likely to cover narrow combinations or processes.

Potential claim areas include:

• Olanzapine ODT compositions.
• Taste-masked olanzapine particles.
• Olanzapine-containing films, granules, or pellets.
• Long-acting olanzapine suspensions.
• Defined olanzapine pamoate particle characteristics.
• Suspension vehicles and reconstitution systems.
• Manufacturing processes that improve particle uniformity.
• Packaging systems that limit moisture or light exposure.
• Combination products with adherence-monitoring or administration technology.

Patent strength depends on claim breadth and design-around difficulty. A claim covering "olanzapine and mannitol" is weak because it relies on common excipients. A claim requiring a specific coated particle architecture, release profile, and measurable performance threshold is generally more defensible, provided the specification supports the ranges and the prior art does not disclose them.

How strong is the patent estate for olanzapine long-acting injection?

Zyprexa Relprevv is the most technically protected and commercially difficult olanzapine presentation. The product uses olanzapine pamoate monohydrate, a poorly soluble salt designed for sustained intramuscular release. The product is supplied for suspension and requires administration by trained personnel.

The principal barriers are not only patents. They include:

• Salt and solid-state control.
• Particle-size distribution.
• Sedimentation and syringeability.
• Reconstitution performance.
• Dose uniformity.
• Injection-site tolerability.
• Long-term release reproducibility.
• Manufacturing containment and aseptic processing.
• Post-injection delirium/sedation syndrome risk.
• A mandatory observation requirement after administration.

The FDA-approved label requires patients receiving Zyprexa Relprevv to be observed for at least three hours after injection because of the risk of post-injection delirium and sedation syndrome (FDA, 2024b). That requirement increases the total cost of care and limits adoption, even when the formulation itself has strong adherence benefits.

A competing long-acting product could pursue a differentiated salt, polymeric microsphere, in situ depot, nanocrystal, or alternative injectable suspension. Each route presents substantial development risk. The commercial opportunity is strongest in markets where reduced dosing frequency has high value and clinical infrastructure can support administration and monitoring.

What patent litigation and Paragraph IV risks affect olanzapine?

Olanzapine's main U.S. patent disputes occurred during the transition to generic entry. Paragraph IV activity focused on the compound and formulation patents associated with Zyprexa and Zyprexa Zydis. Because the major patents are now expired, a new generic tablet or ODT generally faces lower patent litigation risk than a protected new molecular entity.

Current risks are more likely to involve:

• Narrow ODT composition patents.
• Taste-masking patents.
• Long-acting injectable patents.
• Patent infringement allegations based on manufacturing processes.
• Trade-secret disputes involving particle engineering or scale-up.
• Regulatory exclusivity for a new indication or delivery system.
• State-level substitution and product liability exposure.

A generic applicant should review the current FDA Orange Book listings for each reference product and perform a jurisdiction-specific freedom-to-operate analysis. Orange Book listings can change as patents are added, delisted, or expire, and an expired patent can remain relevant to historical litigation even when it no longer blocks approval (FDA, 2024a).

What is the generic launch opportunity for olanzapine?

The market divides into three commercial tiers.

Segment	Entry barrier	Margin outlook	Main opportunity
Standard tablets	Low	Low	Low-cost, reliable supply
ODTs	Moderate	Moderate	Taste masking, packaging, adherence
Long-acting injection	High	Higher potential	Depot technology, specialty distribution, hospital use

Standard tablets are suitable for large-scale generic manufacturers with low-cost API supply and strong procurement access. The primary competitive variables are price, supply continuity, product quality, and tender participation.

ODTs can command better economics where patients have swallowing difficulty, poor adherence, or a need for administration without water. The commercial proposition must be supported by patient preference, pharmacy substitution rules, and a meaningful improvement over existing ODT products.

Long-acting products can support higher prices, but development costs and operational complexity are materially higher. A new injectable must overcome the reference product's safety-monitoring burden or demonstrate a clear dosing, administration, or pharmacokinetic advantage.

How does olanzapine compare with competing atypical antipsychotics?

Olanzapine competes with generic risperidone, quetiapine, aripiprazole, ziprasidone, lurasidone, and long-acting products such as paliperidone and aripiprazole injections.

Drug	Formulation opportunity	Key commercial issue
Olanzapine	ODT, depot, taste-masked oral products	Weight gain and metabolic monitoring
Risperidone	ODT, oral solution, microspheres, implants	Broad generic competition
Quetiapine	Immediate-release and extended-release tablets	High volume and intense pricing
Aripiprazole	ODT, oral solution, long-acting injection	Strong depot competition
Paliperidone	Monthly, three-month, and six-month injections	High administration and patent barriers
Lurasidone	Tablets and solid-dispersion systems	Food-dependent administration and historical exclusivity

Olanzapine's formulation value is strongest when a product reduces swallowing burden or provides controlled exposure. Its principal clinical-commercial limitation is metabolic adverse-effect concern, which may restrict use despite low acquisition cost.

What licensing and partnership opportunities exist?

Licensing opportunities are most credible in four areas:

1. ODT technology that combines rapid disintegration with superior taste masking.
2. Long-acting injectable platforms capable of reducing monitoring or injection frequency.
3. Pediatric or geriatric liquid and multiparticulate systems.
4. API particle-engineering platforms that improve dissolution and content uniformity.

A generic manufacturer may license a formulation platform rather than acquire an olanzapine-specific patent. The value of the deal depends on whether the technology supports a differentiated regulatory pathway, reduces bioequivalence risk, or protects manufacturing know-how.

For an originator or specialty company, a regional licensing strategy may target markets where branded depot products remain commercially relevant and generic penetration is lower. For a generic company, the most practical partnership is often a supply-and-development agreement covering API, taste-masked granules, or a complete ODT manufacturing process.

What geographic coverage matters for olanzapine patents?

U.S. compound protection has expired, but formulation and process rights must be reviewed separately in each jurisdiction. Patent families should be screened across:

• United States.
• European Patent Convention states.
• Japan.
• China.
• South Korea.
• India.
• Brazil.
• Canada.
• Australia.

Regulatory and substitution rules vary. An ODT may receive limited commercial benefit in a market where pharmacists routinely substitute for the lowest-cost tablet. A depot product may receive stronger protection from hospital protocols, procurement contracts, and administration infrastructure than from patents alone.

Manufacturing location also affects opportunity. India and China have substantial generic capacity, while U.S. and European supply agreements can support premium positioning based on continuity, serialization, and regulatory reliability.

What is the revenue exposure from olanzapine patent expiry?

Olanzapine historically generated multibillion-dollar annual sales for Eli Lilly before generic entry. The loss of U.S. exclusivity produced a sharp decline in originator revenue and transferred volume to generic manufacturers. Current revenue exposure is concentrated in:

• High-volume generic tablets.
• Branded or specialty ODT products.
• Long-acting injectable therapy.
• Hospital and institutional contracts.
• International markets with slower generic substitution.

The largest risk for a new entrant is overestimating the value of the molecule itself. Olanzapine is widely available. Revenue depends on formulation differentiation, channel access, manufacturing cost, and clinical positioning.

Key Takeaways

• Olanzapine compound exclusivity expired in the United States in 2011.
• Standard tablets are mature, price-sensitive generic products.
• ODTs offer the most practical excipient-led opportunity.
• Taste masking, rapid disintegration, moisture control, and tablet robustness are the core ODT design targets.
• Long-acting olanzapine has higher technical and commercial barriers, particularly because of post-injection monitoring requirements.
• New patents should focus on defined particle systems, coating architectures, release profiles, manufacturing processes, and product performance.
• Common excipients alone are unlikely to support strong patent protection.
• Current competitive risk is lower for standard tablets and higher for differentiated ODT and depot products.
• Geographic strategy, substitution rules, hospital access, and supply reliability may matter as much as patent term.
• The strongest business case is a formulation that improves adherence or administration while producing a defensible regulatory and manufacturing advantage.

FAQs

Can a new olanzapine tablet still receive patent protection?

Yes. Protection would need to cover a novel and non-obvious formulation, process, solid-state form, release profile, or delivery system. A routine excipient substitution is unlikely to support durable claims.

Is olanzapine ODT a better commercial opportunity than standard olanzapine tablets?

Usually. ODTs can support differentiation through taste masking, rapid disintegration, packaging, and patient convenience. The opportunity remains subject to generic substitution and existing ODT competition.

Does olanzapine have biosimilar risk?

No. Olanzapine is a chemically synthesized small molecule, not a biologic. Competition occurs through ANDA generic products or, for certain differentiated products, a 505(b)(2) pathway.

What is the main regulatory barrier for a new olanzapine depot injection?

The main barriers are reproducible long-term release, injectable particle control, reconstitution, clinical comparability, and management of post-injection safety. The reference product's mandatory observation requirement also affects commercial adoption.

Which excipient is most important in an olanzapine ODT?

No single excipient determines product performance. The critical system combines a rapidly wetting filler, an efficient superdisintegrant, a taste-masking approach, controlled compression, and moisture-protective packaging.

References

1. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

2. Food and Drug Administration. (2024b). Zyprexa Relprevv prescribing information. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024c). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/daf/

4. Eli Lilly and Company. (1996). Zyprexa NDA approval materials and prescribing information. U.S. Food and Drug Administration.

5. United States Patent and Trademark Office. (2024). Patent Center and patent term information. https://patentcenter.uspto.gov/

6. United States Patent No. 5,229,382. (1993). Thienobenzodiazepine derivatives. U.S. Patent and Trademark Office.